Association of prognostic value of primary tumor location in stage III colon cancer WithRAS andBRAF mutational status

Julien Taieb, Hampig Raphael Kourie, Jean François Emile, Karine Le Malicot, Ralyath Balogoun, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean Luc Van Laethem, Claire Mulot, Olivier Bouché, Thomas Aparicio, Pierre Michel, Josef Thaler, John Bridgewater, Eric Van Cutsem, Géraldine Perkins, Come Lepage, Ramon Salazar, Pierre Laurent-Puig

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)


© 2018 American Medical Association. IMPORTANCE We know of no data on the prognostic value of primary tumor location (PTL) according to BRAF, RAS, and microsatellite instability (MSI) status in patients who have undergone resection for colon cancer (CC) and have been treated with current standard adjuvant chemotherapy. OBJECTIVE To determine the prognostic and predictive value of PTL according to BRAF, RAS, and MSI status in patients with stage III CC receiving adjuvant treatment with FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) with or without cetuximab. DESIGN, SETTING, AND PARTICIPANTS This post hoc analysis included patients with available tumor blocks of resected stage III colon adenocarcinoma who participated in the Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 phase 3 randomized trial. Among the 2559 patients who underwent randomization, 1900 were screened by next-generation sequencing, which showed that 1869 had full information concerning PTL.We categorized primary tumor site as located proximal (right) or distal (left) to the splenic flexure. MAIN OUTCOMES AND MEASURES The associations between PTL (right- vs left-sided) and disease-free survival (DFS), survival after relapse (SAR), and overall survival (OS) were assessed by Cox models and adjusted for clinical and pathological features, treatment, and MSI, BRAF, and RAS status. RESULTS Among the 1869 patients (1056 [57%] male; mean [SD] age, 59.4 [9.5] years) with full molecular data analyzed, 755 (40%) had a right-sided tumor, 164 (10%) had MSI, 942 (50%) had RAS mutations, and 212 (11%) had BRAF mutations. Right-sided tumor location was not prognostic for DFS in the whole population but was associated with a shorter SAR (hazard ratio [HR], 1.54; 95%CI, 1.23-1.93; P = .001) and OS (HR, 1.25; 95%CI, 1.02-1.54; P = .03). When looking at DFS in the different molecular subgroups, we found similar results for microsatellite-stable tumors and tumors with MSI; a better DFS in right-sided vs left-sided tumors in patients with RAS mutations (HR, 0.80; 95%CI, 0.64-1.00; P = .046); and a worse DFS in right-sided vs left-sided tumors in patients with RAS and BRAF double wild type (HR, 1.39; 95%CI, 1.01-1.92; P = .04). These results were found independently of the treatment received, and no beneficial effect of cetuximab on DFS or OS was observed in left-sided tumors. CONCLUSIONS AND RELEVANCE Although right-sided tumor location is associated with poor survival in patients with metastatic CC as previously reported, the association with disease recurrence appears to vary for patients with stage III CC and RAS or BRAF mutations vs those with double wild type.
Original languageEnglish
Article numbere173695
JournalJAMA Oncology
Issue number7
Publication statusPublished - 1 Jul 2018


Dive into the research topics of 'Association of prognostic value of primary tumor location in stage III colon cancer WithRAS andBRAF mutational status'. Together they form a unique fingerprint.

Cite this